Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

Prospective French Study on ACQUIred Haemophilia Treatment With Recombinant Factor VIIa (NovoSeven®) A Prospective Observational Study on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for the Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

This study is conducted in Europe. The aim of this prospective, observational study are to describe the different clinical practice and detailed haemostatic management of activated recombinant human factor VII (NovoSeven®) in patients with acquired haemophilia in France. The secondary aim is to assess the primary haemostasis disorder associated with the coagulation disorders, if available.

Inclusion Criteria:

• Diagnosed with acquired haemophilia
• Treated with activated recombinant human factor VII as first line treatment
• Treated with activated recombinant human factor VII after January 2011

Exclusion Criteria:

• Patients with first diagnosis before january 2010 and having a relapse after january 2011
• Known hypersensitivity to NovoSeven®, or to mouse, hamster or bovine protein